Bristol Myers Squibb Gains EU Approval for Sotyktu as First TYK2 Inhibitor in Psoriatic Arthritis

With the European Medicines Agency approval of Sotyktu (deucravacitinib) for active psoriatic arthritis now confirmed, Bristol Myers Squibb faces an immediate operational question: whether existing API sourcing arrangements and batch scale-up protocols are positioned to meet EU market demand for a novel therapeutic class with no prior regional precedent in this indication.

Sotyktu is the first and only TYK2 inhibitor approved in the European Union for psoriatic arthritis, extending a once-daily oral mechanism that BMS had previously secured for plaque psoriasis. The psoriatic arthritis population represents a distinct patient segment, and commercial supply planning for the expanded indication will require manufacturers to revisit validated batch sizes, release testing parameters, and any indication-specific labelling obligations under EU GMP frameworks.

For QA directors and regulatory affairs leads, the TYK2 inhibitor class introduces selectivity considerations that differentiate it from JAK inhibitors already established in the immunology space. Deucravacitinib's allosteric mechanism means that any post-approval manufacturing changes, including site transfers or process optimisations, will need to demonstrate that selectivity profiles remain within approved specifications, a nuance that carries weight during EMA variation submissions.

Supply chain leads should note that small-molecule oral therapies at commercial scale in the EU operate under 21 CFR Part 211 equivalents within the EudraLex Volume 4 framework, and any API sourcing from non-EU sites will require current GMP certification aligned with mutual recognition agreements. BMS has not publicly disclosed its EU manufacturing or API supply network for Sotyktu, leaving third-party contract manufacturers and CDMOs to monitor whether partnership opportunities emerge as volumes scale.

The approval also lands as the EU immunology market for oral small molecules continues to attract regulatory scrutiny around long-term safety data requirements, meaning pharmacovigilance infrastructure and PSUR scheduling will be active compliance checkpoints for the BMS regulatory team through the near term.

The measurable outcome to track is the timeline between this approval and BMS's first EU commercial batch release for the psoriatic arthritis indication, which will signal how prepared the supply chain was ahead of the regulatory decision.

Source: Indian Pharma Post via Media4Growth, 10 May 2026.